Calamos Advisors LLC Has $6.89 Million Stake in Zimmer Biomet Holdings Inc (NYSE:ZBH)

Calamos Advisors LLC grew its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 9.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 50,159 shares of the medical equipment provider’s stock after acquiring an additional 4,350 shares during the period. Calamos Advisors LLC’s holdings in Zimmer Biomet were worth $6,885,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Van ECK Associates Corp lifted its holdings in shares of Zimmer Biomet by 3.3% during the 2nd quarter. Van ECK Associates Corp now owns 470,061 shares of the medical equipment provider’s stock valued at $55,345,000 after buying an additional 14,832 shares during the last quarter. Hartford Investment Management Co. lifted its holdings in shares of Zimmer Biomet by 0.7% during the 2nd quarter. Hartford Investment Management Co. now owns 28,711 shares of the medical equipment provider’s stock valued at $3,380,000 after buying an additional 208 shares during the last quarter. Charter Trust Co. lifted its holdings in shares of Zimmer Biomet by 5.5% during the 2nd quarter. Charter Trust Co. now owns 1,793 shares of the medical equipment provider’s stock valued at $211,000 after buying an additional 93 shares during the last quarter. National Asset Management Inc. acquired a new stake in shares of Zimmer Biomet during the 2nd quarter valued at about $283,000. Finally, AXA lifted its holdings in shares of Zimmer Biomet by 77.6% during the 2nd quarter. AXA now owns 346,858 shares of the medical equipment provider’s stock valued at $40,839,000 after buying an additional 151,607 shares during the last quarter. Institutional investors and hedge funds own 87.81% of the company’s stock.

Shares of NYSE ZBH opened at $134.82 on Wednesday. The company has a quick ratio of 0.56, a current ratio of 1.19 and a debt-to-equity ratio of 0.58. The business’s 50 day moving average is $137.30 and its two-hundred day moving average is $127.69. The company has a market cap of $28.25 billion, a P/E ratio of 17.65, a P/E/G ratio of 2.61 and a beta of 1.16. Zimmer Biomet Holdings Inc has a 12 month low of $96.99 and a 12 month high of $143.57.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Friday, July 26th. The medical equipment provider reported $1.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.91 by $0.02. The company had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.98 billion. Zimmer Biomet had a positive return on equity of 13.40% and a negative net margin of 4.56%. The company’s revenue for the quarter was down .9% on a year-over-year basis. During the same period in the previous year, the business posted $1.92 EPS. Sell-side analysts expect that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.71%. The ex-dividend date is Friday, September 27th. Zimmer Biomet’s dividend payout ratio is currently 12.57%.

Several equities research analysts recently weighed in on ZBH shares. Wells Fargo & Co boosted their target price on Zimmer Biomet from $150.00 to $158.00 and gave the stock an “outperform” rating in a report on Monday, September 9th. ValuEngine lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Wednesday, August 21st. Raymond James boosted their target price on Zimmer Biomet from $145.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, July 29th. Credit Suisse Group boosted their target price on Zimmer Biomet from $101.00 to $120.00 and gave the stock an “underperform” rating in a report on Monday, July 29th. Finally, Robert W. Baird upgraded Zimmer Biomet from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $132.00 to $154.00 in a report on Monday, July 29th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $145.40.

In other Zimmer Biomet news, VP Chad F. Phipps sold 32,800 shares of Zimmer Biomet stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $140.00, for a total value of $4,592,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Chad F. Phipps sold 7,000 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $138.28, for a total value of $967,960.00. Following the completion of the transaction, the vice president now directly owns 37,722 shares in the company, valued at $5,216,198.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,391 shares of company stock worth $5,642,274. Company insiders own 0.72% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

See Also: Overbought

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit